Haemonetics (HAE) return on equity (ROE)

Return on equity · fiscal 2026
12.2%

Haemonetics (HAE) earned a return on equity of 12.2% in fiscal 2026 (the year ended March 31, 2026). That is 8.2 percentage points lower than the 20.4% of fiscal 2025. Figures as of 17 Nov 2026, 21:53 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2026
12.2%
Change on fiscal 2025
−8.2 pts
Highest on record
20.4%fiscal 2025
Lowest on record
-7.7%fiscal 2016
Fiscal years on record
182009–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Haemonetics return on equity (ROE), in more detail

Across the 18 fiscal years on record (2009–2026), the highest was 20.4% in fiscal 2025 and the lowest -7.7% in fiscal 2016. The fiscal 2026 figure is higher than in 76% of the 17 earlier fiscal years on record, whose median is 9.1%.

History · 18 fiscal years

Return on equity by fiscal year

Haemonetics return on equity (ROE), year by year

Haemonetics (HAE) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202612.2% 8.2 pts down
202520.4% 8.2 pts up
202412.2% 1.9 pts down
202314.1% 8.3 pts up
20225.8% 5.1 pts down
202110.9% 2.2 pts down
202013.0% 4.8 pts up
20198.2% 2.2 pts up
20186.1% 9.6 pts up
2017-3.6% 4.2 pts up
2016-7.7% 9.7 pts down
20152.0% 2.1 pts down
20144.2% 0.8 pts down
20135.0% 4.1 pts down
20129.1% 2.5 pts down
201111.7% 1.8 pts up
20109.8% 1.1 pts down
200911.0%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Haemonetics and comparable companies
CompanyReturn on equityFiscal year
Hims & Hers Health HIMS23.7%2025
PTC Therapeutics PTCT-36432.6%2021
Haemonetics HAE12.2%2026
Erasca ERAS-38.3%2025
Concentra Group Holdings Parent CON42.3%2025
Merit Medical Systems MMSI8.1%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HAE

Haemonetics, figure by figure

Haemonetics (HAE) overview: price, valuation and scorecardAll health care companies by market value

Haemonetics return on equity (ROE): questions and answers

What is Haemonetics's return on equity?

Haemonetics (HAE) earned a return on equity of 12.2% in fiscal 2026 (the year ended March 31, 2026). That is 8.2 percentage points lower than the 20.4% of fiscal 2025.

Is Haemonetics's return on equity high or low compared with its own history?

The fiscal 2026 figure is higher than in 76% of the 17 earlier fiscal years on record, whose median is 9.1%.

What are the highest and lowest return on equity figures on record for Haemonetics?

Across the 18 fiscal years on record (2009–2026), the highest was 20.4% in fiscal 2025 and the lowest -7.7% in fiscal 2016.

How is Haemonetics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Haemonetics (HAE) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/HAE/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.